Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4,

Slides:

Advertisements

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Advertisements

Secretory IgA induces antigen-independent eosinophil survival and cytokine production without inducing effector functions Kathleen R. Bartemes, BA, Kate.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Expression of FcγRIII (CD16) on human peripheral blood eosinophils increases in allergic conditions Francis Davoine, MSc, Sophie Lavigne, MSc, Jamila.

Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison.

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

The effects of upper respiratory infection on T-cell proliferation and steroid sensitivity of asthmatics Elcio O. Vianna, MD, PhD, Jay Westcott, PhD,

Predominance of type 2 cytokine–producing CD4+ and CD8+ cells in patients with atopic dermatitis Masatoshi Nakazawa, DVMa, Nakako Sugi, MDb, Hiroshi.

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy Margarete Focke-Tejkl, PhD, Milena.

Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug- induced cutaneous eruptions Nikhil Yawalkar, MD, Maithili Shrikhande,

The effect of omalizumab on nasal allergic inflammation

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.

Fuad M. Baroody, MD, Se-Hoon Suh, MD, Robert M. Naclerio, MD

T lymphocytes in asthma: Bronchial versus peripheral responses

Practice Notes from the AAAAI

Allergy-related outcomes in relation to serum IgE: Results from the National Health and Nutrition Examination Survey Päivi M. Salo, PhD, Agustin.

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Requirements for allergen-induced airway inflammation and hyperreactivity in CD4- deficient and CD4-sufficient HLA-DQ transgenic mice Svetlana P. Chapoval,

Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity

Nobuhisa Terada, MDa, Akiyoshi Konno, MDb, Kiyoshi Togawa, MDa

Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic.

A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations John H. Toogood, MD,

Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma Donavan T. Cheng, PhD, Cynthia Ma,

Circadian variation of sputum inflammatory cells in mild asthma

Basophils and eosinophils in allergic rhinitis

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Recruitment of T cells to the lung in response to antigen challenge

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production Henk F. Kauffman, PhD, J.F.Chris.

Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy Eva Wollmann,

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

John A. Eckman, MD, Patricia M

Eosinophilia and gastrointestinal symptoms after ingestion of shiitake mushrooms Aaron M. Levy, MDa, Hirohito Kita, MDb, Sidney F. Phillips, MDa, Paul.

Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids Keisuke.

Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation Alex.

Differential regulation of cytokine expression after allergen exposure of sensitized rats by cyclosporin A and corticosteroids: Relationship to bronchial.

Mast cells regulate IFN-γ expression in the skin and circulating IgE levels in allergen- induced skin inflammation Harri Alenius, PhD, Dhafer Laouini,

Fetal and neonatal IL-13 production during pregnancy and at birth and subsequent development of atopic symptoms Toby J. Williams, Catherine A. Jones,

Harald Renz, MD, Chaya Brodie, PhD, Katherine Bradley, BS, Donald Y. M

Allergic rhinitis Journal of Allergy and Clinical Immunology

Inhibition of human allergic T-cell responses by IL-10–treated dendritic cells: Differences from hydrocortisone-treated dendritic cells Iris Bellinghausen,

Acquisition and alteration of adhesion molecules during cultured human mast cell differentiation Hiroshi Tachimoto, MD, PhD, Sherry A. Hudson, MSB, Bruce.

Loratadine reduces allergen-induced mucosal output of α2-macroglobulin and tryptase in allergic rhinitis Lennart Greiff, MD, PhDa, Carl G.A. Persson,

Ligation of IgE receptors causes an anaphylactic response and neutrophil infiltration but does not induce eosinophilic inflammation in mice Masayuki.

Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation Anthony P. Sampson, PhDa, Emilio Pizzichini, MD, PhDb,

Chemokines in seasonal allergic rhinitis

Seasonal rhinitis and azelastine: Long- or short-term treatment

G. Weyman Price, MDa, b, Angela D. Hogan, MDc, A. Holly Farris, BAa, A

Seasonal intestinal inflammation in patients with birch pollen allergy

Increased adhesion to vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 of eosinophils from patients with asthma Lena Håkansson,

Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis Toyoyuki Hanazawa, MD, PhD, Julio.

In vivo effects of glucocorticoids on IgE production

Changes in sputum counts and airway hyperresponsiveness after budesonide: Monitoring anti-inflammatory response on the basis of surrogate markers of airway.

Alvaro A. Cruz, MD, Robert M

Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects David E. Parry, MD*, William W. Busse, MD, Kris A. Sukow,

Nedocromil sodium and airway inflammation in vivo and in vitro

Monocyte chemotactic proteins in allergen-induced inflammation in the nasal mucosa: Effect of topical corticosteroids Pota Christodoulopoulos, BSca,

Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma Sally E. Wenzel, MD Journal of Allergy and Clinical.

Nasal challenge with allergen leads to maxillary sinus inflammation

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

IL-4– and IL-5–positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects Luis T. Barata,

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy Kayhan T. Nouri-Aria, PhD, FRCPath, Charles.

Fiftieth Annual Meeting of the American Academy of Allergy and Immunology: Anaheim, California, March 1994 Lawrence M. Lichtenstein, MD, PhD Journal.

Suppression of plasma neutrophil elastase–α1-anti-proteinase complex by adequate replacement therapy in a patient with acquired hypogammaglobulinemia

Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response Meri K Tulic, PhD, Pierre-Olivier Fiset,

Presentation transcript:

Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected Hirohito Kita, MD, Ronald K. Jorgensen, MD, Charles E. Reed, MD, Sandra L. Dunnette, BA, Mark C. Swanson, BA, Kathleen R. Bartemes, BA, Diane Squillace, BA, Judy Blomgren, RN, Kay Bachman, RN, BSN, Gerald J. Gleich, MD Journal of Allergy and Clinical Immunology Volume 106, Issue 3, Pages 521-529 (September 2000) DOI: 10.1067/mai.2000.108430 Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 1 Short ragweed pollen counts in Rochester, Minnesota, during the 1995 ragweed hay fever season (gray area) . Mean daily nasal symptom scores of the placebo-treated (solid black line , n = 14) and budesonide-treated (dashed line , n = 10) patients are represented from July 24, 1995, through October 26, 1995 (weeks 1-14). Statistical analysis comparing nasal symptoms between the placebo and budesonide groups was performed on symptom scores recorded from August 20, 1995, through September 10, 1995 (arrows) . Journal of Allergy and Clinical Immunology 2000 106, 521-529DOI: (10.1067/mai.2000.108430) Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 2 Comparison of nasal fluid EDN levels. A, Changes in EDN levels (nanograms per milliliter) in the nasal lavage fluid of the placebo (closed circles) and budesonide (open circles) groups during the ragweed hay fever season. The geometric mean values for each group are shown. Asterisks indicate significant differences compared with week 1 (*P < .05, **P < .01). B, Nasal EDN levels (in nanograms per milliliter) preseason (week 1), at peak season (week 6), and off-season (week 27) were compared for each patient group. Each dot represents a patient, and the values for each patient are connected by a line . The geometric mean values are represented by solid bars . C, EDN levels (in nanograms per milliliter) in the nasal lavage fluid of the placebo-treated (n = 14) and budesonide-treated (n = 10) patients obtained at the peak of the ragweed season (week 6). The geometric mean values for each group are represented (solid bars) . Journal of Allergy and Clinical Immunology 2000 106, 521-529DOI: (10.1067/mai.2000.108430) Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 3 Comparison of cytokine levels between groups at the peak of the ragweed season. A, IL-5 levels (in picograms per milliliter) in the nasal lavage fluid of the placebo-treated (n = 14) and budesonide-treated (n = 10) patients at the peak of the ragweed season (week 6). B, IL-4 levels (in picograms per milliliter) in the nasal lavage fluid of the placebo-treated (n = 14) and budesonide-treated (n = 10) patients at the peak of the ragweed season (week 6). C, IL-6 levels (in picograms per milliliter) in the nasal lavage fluid of the placebo-treated (n = 14) and budesonide-treated (n = 10) patients at the peak of the ragweed season (week 6). Geometric mean values for each group are represented by solid bars . Values below the lowest limits of detection are reported as zero. Journal of Allergy and Clinical Immunology 2000 106, 521-529DOI: (10.1067/mai.2000.108430) Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 4 Soluble ICAM-1 (sICAM-1) levels in the nasal lavage fluid of the placebo-treated (n = 14) and budesonide-treated (n = 10) patients at the peak of the ragweed season (week 6). The geometric mean values for each group are represented by solid bars . Journal of Allergy and Clinical Immunology 2000 106, 521-529DOI: (10.1067/mai.2000.108430) Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 5 Comparison of nasal fluid markers of inflammation and symptoms. A, Correlation of EDN with nasal symptoms in the placebo group. B, Correlation of IL-5 with nasal symptoms in the placebo group. C, Correlation of IL-5 with EDN in the placebo group. Journal of Allergy and Clinical Immunology 2000 106, 521-529DOI: (10.1067/mai.2000.108430) Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 6 Cellular activation markers CD11b and CD69 on eosinophils and CD25 on lymphocytes. Cells from nonallergic control subjects, the budesonide group, and the placebo group were analyzed at the ragweed season peak (week 6). The results are expressed as the change in mean fluorescence intensity (ΔMFI) . The change in mean fluorescence intensity was calculated from the specific fluorescence intensity with mAb minus the background fluorescence intensity with control antibody. Mean values for each group are represented by solid bars . A, For CD11b, the budesonide group’s mean change in mean fluorescence intensity of 74 and the placebo group’s change in mean fluorescence intensity of 102 were increased compared with the normal value (P < .05 and P < .005, respectively). B, For CD69, the budesonide group’s mean change in mean fluorescence intensity of 21.7 and the placebo group’s change in mean fluorescence intensity of 20.9 were increased compared with the normal value (P < .001 and P < .005, respectively). C, For CD25, the budesonide group’s mean change in mean fluorescence intensity of 84 and the placebo group’s change in mean fluorescence intensity of 89 were increased compared with the normal value (P < .01 and P < .005, respectively). Journal of Allergy and Clinical Immunology 2000 106, 521-529DOI: (10.1067/mai.2000.108430) Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 7 Comparison of serum ragweed-specific IgE and IgA levels. A, Serum ragweed-specific IgE levels (in nanograms per milliliter) in the placebo (solid circle , n = 14) and budesonide (open circle , n = 10) treatment groups as measured during and several weeks after the ragweed hay fever season. Statistical analysis comparing the two groups was performed on week 11 of the ragweed season, which corresponds with the end of the season. Geometric mean values for each group are represented by solid bars . B, Nasal lavage fluid ragweed-specific IgA levels (in units per milliliter) in the placebo (solid circles , n = 14) and budesonide (open circles , n = 10) treatment groups as measured throughout the ragweed hay fever season. Statistical analysis comparing the two groups was performed at week 11 at the end of the ragweed season and the week with the greatest difference between the two groups. Geometric mean values for each group are represented by solid bars . Journal of Allergy and Clinical Immunology 2000 106, 521-529DOI: (10.1067/mai.2000.108430) Copyright © 2000 Mosby, Inc. Terms and Conditions